Adaptive Biotechnologies (ADPT) is a Great Momentum Stock: Should You Buy? |
Does Adaptive Biotechnologies (ADPT) have what it takes to be a top stock pick for momentum investors? Let's find out. |
zacks.com |
2025-05-09 17:05:49 |
Czytaj oryginał (ang.) |
Does Adaptive Biotechnologies (ADPT) Have the Potential to Rally 26.45% as Wall Street Analysts Expect? |
The consensus price target hints at a 26.5% upside potential for Adaptive Biotechnologies (ADPT). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term. |
zacks.com |
2025-05-08 15:02:16 |
Czytaj oryginał (ang.) |
Has Adaptive Biotechnologies (ADPT) Outpaced Other Medical Stocks This Year? |
Here is how Adaptive Biotechnologies (ADPT) and Centene (CNC) have performed compared to their sector so far this year. |
zacks.com |
2025-05-08 14:45:55 |
Czytaj oryginał (ang.) |
Adaptive Biotechnologies Corporation (ADPT) Q1 2025 Earnings Call Transcript |
Adaptive Biotechnologies Corporation (NASDAQ:ADPT ) Q1 2025 Earnings Conference Call May 1, 2025 4:30 PM ET Company Participants Karina Calzadilla - Head of Investor Relations & FP&A Chad Robins - Chief Executive Officer & Co-Founder Kyle Piskel - Chief Financial Officer Susan Bobulsky - Chief Commercial Officer Conference Call Participants Mark Massaro - BTIG David Westenberg - Piper Sandler Yuko Oku - Morgan Stanley Sebastian Sandler - JPMorgan Tom Stevens - TD Cowen Corey Rosenbaum - Scotia Bank Maggie Boeye - William Blair Operator Good day, and thank you for standing by. Welcome to the Adaptive Biotechnologies First Quarter 2025 Earnings Conference Call. |
seekingalpha.com |
2025-05-02 01:46:51 |
Czytaj oryginał (ang.) |
Adaptive Biotechnologies (ADPT) Q1 Earnings: Taking a Look at Key Metrics Versus Estimates |
The headline numbers for Adaptive Biotechnologies (ADPT) give insight into how the company performed in the quarter ended March 2025, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals. |
zacks.com |
2025-05-02 00:05:41 |
Czytaj oryginał (ang.) |
Adaptive Biotechnologies (ADPT) Reports Q1 Loss, Tops Revenue Estimates |
Adaptive Biotechnologies (ADPT) came out with a quarterly loss of $0.20 per share versus the Zacks Consensus Estimate of a loss of $0.28. This compares to loss of $0.33 per share a year ago. |
zacks.com |
2025-05-01 22:40:53 |
Czytaj oryginał (ang.) |
Adaptive Biotechnologies Reports First Quarter 2025 Financial Results |
SEATTLE, May 01, 2025 (GLOBE NEWSWIRE) -- Adaptive Biotechnologies Corporation (“Adaptive Biotechnologies”) (Nasdaq: ADPT), a commercial stage biotechnology company that aims to translate the genetics of the adaptive immune system into clinical products to diagnose and treat disease, today reported financial results for the quarter ended March 31, 2025. “We had a strong start to 2025 with 34% MRD revenue growth, driven by continued acceleration in clonoSEQ test volume and disciplined execution,” said Chad Robins, chief executive officer and co-founder of Adaptive Biotechnologies. |
globenewswire.com |
2025-05-01 20:05:00 |
Czytaj oryginał (ang.) |
Adaptive Biotechnologies to Report First Quarter 2025 Financial Results on May 1, 2025 |
SEATTLE, April 10, 2025 (GLOBE NEWSWIRE) -- Adaptive Biotechnologies Corporation (Nasdaq: ADPT), a commercial stage biotechnology company that aims to translate the genetics of the adaptive immune system into clinical products to diagnose and treat disease, today announced it will report financial results for the first quarter 2025 after market close on Thursday, May 1, 2025. Company management will webcast a corresponding conference call beginning at 1:30 p.m. Pacific Time / 4:30 p.m. Eastern Time. |
globenewswire.com |
2025-04-10 20:05:00 |
Czytaj oryginał (ang.) |
Adaptive Biotechnologies Receives Expanded Medicare Coverage of clonoSEQ® for Surveillance in Mantle Cell Lymphoma |
clonoSEQ is now covered to monitor for recurrence in MCL patients who are in treatment-free remission clonoSEQ is now covered to monitor for recurrence in MCL patients who are in treatment-free remission |
globenewswire.com |
2025-04-08 12:00:00 |
Czytaj oryginał (ang.) |
Adaptive Biotechnologies Launches Assay Enhancements to Increase clonoSEQ® Sensitivity for Clinical MRD Detection in Diffuse Large B-Cell Lymphoma |
Enhanced assay granted approval by New York State's Clinical Lab Evaluation Program (CLEP) for patients with DLBCL clonoSEQ is the only DLBCL MRD assay available for clinical use and covered by Medicare SEATTLE, March 11, 2025 (GLOBE NEWSWIRE) -- Adaptive Biotechnologies Corporation (Nasdaq: ADPT), a commercial stage biotechnology company that aims to translate the genetics of the adaptive immune system into clinical products to diagnose and treat disease, today announced that it has launched an upgraded version of its clonoSEQ assay for measurable residual disease (MRD) detection in diffuse large B-cell lymphoma (DLBCL) using circulating tumor DNA (ctDNA). The enhanced clonoSEQ assay, which incorporates an optimized DNA extraction methodology and maximizes sample input, delivers a 7-fold increase in sensitivity. |
globenewswire.com |
2025-03-11 10:00:00 |
Czytaj oryginał (ang.) |
Adaptive Biotechnologies (ADPT) Moves to Buy: Rationale Behind the Upgrade |
Adaptive Biotechnologies (ADPT) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term. |
zacks.com |
2025-02-12 15:01:17 |
Czytaj oryginał (ang.) |
Are Medical Stocks Lagging Adaptive Biotechnologies (ADPT) This Year? |
Here is how Adaptive Biotechnologies (ADPT) and Castle Biosciences, Inc. (CSTL) have performed compared to their sector so far this year. |
zacks.com |
2025-02-12 12:40:15 |
Czytaj oryginał (ang.) |
Adaptive Biotechnologies Corporation (ADPT) Q4 2024 Earnings Call Transcript |
Adaptive Biotechnologies Corporation (NASDAQ:ADPT ) Q4 2024 Results Conference Call February 11, 2025 4:30 PM ET Company Participants Karina Calzadilla - Head of IR & FP&A Chad Robins - CEO and Co-Founder Kyle Piskel - CFO Susan Bobulsky - Chief Commercial Officer Sharon Benzeno - Chief Commercial Officer of Immune Medicine Harlan Robins - Co-Founder & Chief Scientific Officer Conference Call Participants Andrew Brackmann - William Blair Rachel Vatnsdal - JPMorgan Mark Massaro - BTIG Sung Ji Nam - Scotiabank Dan Brennan - TD Cowen Tejas Savant - Morgan Stanley Operator Good day, and thank you for standing by. Welcome to the Adaptive Biotechnologies Fourth Quarter and Full Year 2024 Financial Results Conference Call. |
seekingalpha.com |
2025-02-11 21:47:05 |
Czytaj oryginał (ang.) |
Adaptive Biotechnologies (ADPT) Q4 Earnings: Taking a Look at Key Metrics Versus Estimates |
The headline numbers for Adaptive Biotechnologies (ADPT) give insight into how the company performed in the quarter ended December 2024, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals. |
zacks.com |
2025-02-11 21:31:11 |
Czytaj oryginał (ang.) |
Adaptive Biotechnologies (ADPT) Reports Q4 Loss, Tops Revenue Estimates |
Adaptive Biotechnologies (ADPT) came out with a quarterly loss of $0.23 per share versus the Zacks Consensus Estimate of a loss of $0.26. This compares to loss of $0.30 per share a year ago. |
zacks.com |
2025-02-11 20:36:07 |
Czytaj oryginał (ang.) |
Adaptive Biotechnologies Reports Fourth Quarter and Full Year 2024 Financial Results |
SEATTLE, Feb. 11, 2025 (GLOBE NEWSWIRE) -- Adaptive Biotechnologies Corporation (“Adaptive Biotechnologies”) (Nasdaq: ADPT), a commercial stage biotechnology company that aims to translate the genetics of the adaptive immune system into clinical products to diagnose and treat disease, today reported financial results for the fourth quarter and full year ended December 31, 2024. |
globenewswire.com |
2025-02-11 18:05:00 |
Czytaj oryginał (ang.) |
Adaptive Biotechnologies to Participate in Upcoming Investor Conferences |
SEATTLE, Feb. 05, 2025 (GLOBE NEWSWIRE) -- Adaptive Biotechnologies Corporation (“Adaptive Biotechnologies”) (Nasdaq: ADPT), a commercial stage biotechnology company that aims to translate the genetics of the adaptive immune system into clinical products to diagnose and treat disease, today announced it will be participating in the following investor conferences. |
globenewswire.com |
2025-02-05 18:05:00 |
Czytaj oryginał (ang.) |
Adaptive Biotechnologies to Report Fourth Quarter and Full Year 2024 Financial Results on February 11, 2025 |
SEATTLE, Jan. 22, 2025 (GLOBE NEWSWIRE) -- Adaptive Biotechnologies Corporation (Nasdaq: ADPT), a commercial stage biotechnology company that aims to translate the genetics of the adaptive immune system into clinical products to diagnose and treat disease, today announced it will report financial results for the fourth quarter and full year 2024 after market close on Tuesday, February 11, 2025. Company management will webcast a corresponding conference call beginning at 1:30 p.m. Pacific Time / 4:30 p.m. Eastern Time. |
globenewswire.com |
2025-01-22 18:05:00 |
Czytaj oryginał (ang.) |
Is Adaptive Biotechnologies (ADPT) Stock Outpacing Its Medical Peers This Year? |
Here is how Adaptive Biotechnologies (ADPT) and Bio-Rad Laboratories (BIO) have performed compared to their sector so far this year. |
zacks.com |
2025-01-17 12:41:24 |
Czytaj oryginał (ang.) |
Adaptive Biotechnologies (ADPT) Soars 18.0%: Is Further Upside Left in the Stock? |
Adaptive Biotechnologies (ADPT) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the road. |
zacks.com |
2025-01-16 11:35:46 |
Czytaj oryginał (ang.) |
Adaptive Biotechnologies and NeoGenomics Partner to Expand Access to Personalized Disease Monitoring for Blood Cancer Patients |
Pairing Adaptive Biotechnologies' clonoSEQ MRD results with NeoGenomics' COMPASS and CHART assessment services empowers clinicians and patients with meaningful insights across the treatment continuum Pairing Adaptive Biotechnologies' clonoSEQ MRD results with NeoGenomics' COMPASS and CHART assessment services empowers clinicians and patients with meaningful insights across the treatment continuum |
globenewswire.com |
2025-01-14 09:30:00 |
Czytaj oryginał (ang.) |
Adaptive Biotechnologies Announces Clinical Lab Fee Schedule Rate of $2,007 for clonoSEQ® Test for Minimal Residual Disease Assessment is Effective as of January 1st, 2025 |
SEATTLE, Jan. 07, 2025 (GLOBE NEWSWIRE) -- Adaptive Biotechnologies Corporation (Nasdaq: ADPT), a commercial stage biotechnology company that aims to translate the genetics of the adaptive immune system into clinical products to diagnose and treat disease, announced today that the new Medicare Clinical Laboratory Fee Schedule (CLFS) rate for its next-generation sequencing (NGS)-based clonoSEQ® test for minimal – or measurable – residual disease (MRD) assessment is now in effect as of January 1, 2025. The CLFS rate for clonoSEQ (PLA 0364U) was set at $2,007, consistent with the final gapfill rate recommendation for the test. |
globenewswire.com |
2025-01-07 09:30:00 |
Czytaj oryginał (ang.) |
Adaptive Biotechnologies to Present at the 43rd Annual J.P. Morgan Healthcare Conference |
SEATTLE, Jan. 02, 2025 (GLOBE NEWSWIRE) -- Adaptive Biotechnologies Corporation (Nasdaq: ADPT), a commercial stage biotechnology company that aims to translate the genetics of the adaptive immune system into clinical products to diagnose and treat disease, today announced it will be participating in the upcoming 43rd Annual J.P. Morgan Healthcare Conference in San Francisco, CA. |
globenewswire.com |
2025-01-02 18:05:00 |
Czytaj oryginał (ang.) |
Adaptive Biotechnologies Announces New Data at the 66th ASH Annual Meeting Highlighting Advances in MRD Testing with clonoSEQ® and Its Impact on Blood Cancer Treatment Decisions |
New data demonstrate the actionability of clonoSEQ for tailoring treatment decisions in patients with MCL, CLL, MM and ALL |
globenewswire.com |
2024-12-07 20:30:00 |
Czytaj oryginał (ang.) |
Adaptive Biotechnologies Announces Over 65 Abstracts Featuring clonoSEQ® MRD Testing Across a Range of Blood Cancers to be Presented at the 66th ASH Annual Meeting |
SEATTLE, Dec. 03, 2024 (GLOBE NEWSWIRE) -- Adaptive Biotechnologies Corporation (Nasdaq: ADPT), a commercial stage biotechnology company that aims to translate the genetics of the adaptive immune system into clinical products to diagnose and treat disease, announced that its next-generation sequencing (NGS)-based clonoSEQ® test for measurable residual disease (MRD) assessment will be included in more than 65 abstracts across eight different types of blood cancer at the 66th Annual Meeting of the American Society of Hematology (ASH) taking place December 7-10, 2024, in San Diego. Among these abstracts are a plenary session presentation, a late-breaking abstract and 25 other oral presentations. |
globenewswire.com |
2024-12-03 09:30:00 |
Czytaj oryginał (ang.) |
Is Adaptive Biotechnologies (ADPT) Outperforming Other Medical Stocks This Year? |
Here is how Adaptive Biotechnologies (ADPT) and Cardinal Health (CAH) have performed compared to their sector so far this year. |
zacks.com |
2024-11-29 12:40:29 |
Czytaj oryginał (ang.) |
Adaptive Biotechnologies: Making Some Progress |
Adaptive Biotechnologies posted strong Q3 results, beating expectations and reducing losses, while management has done a good job of reducing quarterly cash burn rates. The company's MRD segment, driven by clonoSEQ, continues to show significant growth, and the company's balance sheet remains strong. An updated analysis around Adaptive Biotechnologies follows in the paragraphs below. |
seekingalpha.com |
2024-11-26 12:53:00 |
Czytaj oryginał (ang.) |
Wall Street Analysts Predict a 31.36% Upside in Adaptive Biotechnologies (ADPT): Here's What You Should Know |
The consensus price target hints at a 31.4% upside potential for Adaptive Biotechnologies (ADPT). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term. |
zacks.com |
2024-11-15 13:00:40 |
Czytaj oryginał (ang.) |
Adaptive Biotechnologies Corporation (ADPT) Q3 2024 Earnings Call Transcript |
Adaptive Biotechnologies Corporation (NASDAQ:ADPT ) Q3 2024 Earnings Conference Call November 7, 2024 4:30 PM ET Company Participants Karina Calzadilla - Head of IR Chad Robins - CEO and Co-Founder Kyle Piskel - CFO Susan Bobulsky - Chief Commercial Officer Conference Call Participants Dan Brennan - TD Cowen Mark Massaro - BTIG Matt Sykes - Goldman Sachs Maggie Boeye - William Blair Corey Rosenbaum - Scotiabank Operator Good day, and welcome to Adaptive Biotechnologies Third Quarter Financial Results [Operator Instructions]. As a reminder, this call may be recorded. |
seekingalpha.com |
2024-11-07 23:57:07 |
Czytaj oryginał (ang.) |
Adaptive Biotechnologies (ADPT) Q3 Earnings: Taking a Look at Key Metrics Versus Estimates |
While the top- and bottom-line numbers for Adaptive Biotechnologies (ADPT) give a sense of how the business performed in the quarter ended September 2024, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values. |
zacks.com |
2024-11-07 21:30:47 |
Czytaj oryginał (ang.) |
Adaptive Biotechnologies (ADPT) Reports Q3 Loss, Tops Revenue Estimates |
Adaptive Biotechnologies (ADPT) came out with a quarterly loss of $0.22 per share versus the Zacks Consensus Estimate of a loss of $0.30. This compares to loss of $0.35 per share a year ago. |
zacks.com |
2024-11-07 21:15:36 |
Czytaj oryginał (ang.) |
Adaptive Biotechnologies Receives Expanded Medicare Coverage of clonoSEQ® for Assessing Measurable Residual Disease in Mantle Cell Lymphoma |
clonoSEQ is the first and only assay to receive Medicare coverage for MRD assessment in MCL Coverage leverages new Medicare episode pricing established based on updated clonoSEQ gapfill rate SEATTLE, Nov. 07, 2024 (GLOBE NEWSWIRE) -- Adaptive Biotechnologies Corporation (Nasdaq: ADPT), a commercial stage biotechnology company that aims to translate the genetics of the adaptive immune system into clinical products to diagnose and treat disease, today announced that Palmetto GBA, a Medicare Administrative Contractor (MAC) that assesses diagnostic technologies through its Molecular Diagnostics Services Program (MolDX), has expanded coverage of clonoSEQ® to include detection and monitoring of measurable residual disease (MRD) in Medicare patients with mantle cell lymphoma (MCL). MCL is a sub-type of non-Hodgkin lymphoma (NHL) with an annual incidence of approximately 4,000 cases per year in the United States.1 It is an aggressive disease, and most patients will relapse repeatedly; some shortly after frontline therapy, while others as late as 15 years after initial remission.2 , 3 Given this challenging and variable course of disease, it is critical to effectively assess depth of response in patients undergoing treatment and monitor for recurrence or disease progression following remission. |
globenewswire.com |
2024-11-07 09:30:00 |
Czytaj oryginał (ang.) |
Adaptive Biotechnologies to Report Third Quarter 2024 Financial Results on November 7, 2024 |
SEATTLE, Oct. 09, 2024 (GLOBE NEWSWIRE) -- Adaptive Biotechnologies Corporation (Nasdaq: ADPT), a commercial stage biotechnology company that aims to translate the genetics of the adaptive immune system into clinical products to diagnose and treat disease, today announced it will report financial results for the third quarter 2024 after market close on Thursday, November 7, 2024. Company management will webcast a corresponding conference call beginning at 1:30 p.m. Pacific Time / 4:30 p.m. Eastern Time. |
globenewswire.com |
2024-10-09 20:05:00 |
Czytaj oryginał (ang.) |
Adaptive Announces IVDR Certification for clonoSEQ® in European Union |
clonoSEQ is the first IVDR-certified test to detect minimal residual disease in patients with lymphoid malignancies clonoSEQ is the first IVDR-certified test to detect minimal residual disease in patients with lymphoid malignancies |
globenewswire.com |
2024-08-29 11:30:00 |
Czytaj oryginał (ang.) |
Adaptive Biotechnologies to Participate in the Morgan Stanley 22nd Annual Global Healthcare Conference |
SEATTLE, Aug. 22, 2024 (GLOBE NEWSWIRE) -- Adaptive Biotechnologies Corporation (Nasdaq: ADPT), a commercial stage biotechnology company that aims to translate the genetics of the adaptive immune system into clinical products to diagnose and treat disease, today announced it will be participating in the upcoming Morgan Stanley 22nd Annual Global Healthcare Conference in New York, NY. |
globenewswire.com |
2024-08-22 20:03:00 |
Czytaj oryginał (ang.) |
Adaptive Biotechnologies Corporation (ADPT) Q2 2024 Earnings Call Transcript |
Adaptive Biotechnologies Corporation (NASDAQ:ADPT ) Q2 2024 Earnings Conference Call August 1, 2024 4:30 PM ET Company Participants Karina Calzadilla – Head-Investor Relations Chad Robins – Chief Executive Officer and Co-Founder Kyle Piskel – Chief Financial Officer Susan Bobulsky – Chief Commercial Officer-MRD Conference Call Participants Mark Massaro – BTIG David Westenberg – Piper Sandler Tejas Savant – Morgan Stanley Dan Brennan – TD Cowen Andrew Brackmann – William Blair Rachel Vatnsdal – JPMorgan Sung Ji Nam – Scotiabank Operator Good day and thank you for standing by. Welcome to the Adaptive Biotechnologies Second Quarter 2024 Earnings Call. |
seekingalpha.com |
2024-08-02 02:25:25 |
Czytaj oryginał (ang.) |
Adaptive Biotechnologies (ADPT) Q2 Earnings: Taking a Look at Key Metrics Versus Estimates |
Although the revenue and EPS for Adaptive Biotechnologies (ADPT) give a sense of how its business performed in the quarter ended June 2024, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers. |
zacks.com |
2024-08-02 00:00:28 |
Czytaj oryginał (ang.) |
Adaptive Biotechnologies (ADPT) Reports Q2 Loss, Tops Revenue Estimates |
Adaptive Biotechnologies (ADPT) came out with a quarterly loss of $0.26 per share versus the Zacks Consensus Estimate of a loss of $0.32. This compares to loss of $0.33 per share a year ago. |
zacks.com |
2024-08-01 23:20:25 |
Czytaj oryginał (ang.) |
Adaptive Biotechnologies Reports Second Quarter 2024 Financial Results |
SEATTLE, Aug. 01, 2024 (GLOBE NEWSWIRE) -- Adaptive Biotechnologies Corporation (“Adaptive Biotechnologies”) (Nasdaq: ADPT), a commercial stage biotechnology company that aims to translate the genetics of the adaptive immune system into clinical products to diagnose and treat disease, today reported financial results for the quarter ended June 30, 2024. |
globenewswire.com |
2024-08-01 20:05:00 |
Czytaj oryginał (ang.) |
3 Precision Medicine Stocks Tailoring Treatments |
Two elements favor the case for acquiring precision medicine stocks. First, the obvious point: barring extraordinary circumstances, the broader healthcare ecosystem will always be relevant. |
investorplace.com |
2024-07-21 10:00:00 |
Czytaj oryginał (ang.) |
Adaptive Biotechnologies to Report Second Quarter 2024 Financial Results on August 1, 2024 |
SEATTLE, July 11, 2024 (GLOBE NEWSWIRE) -- Adaptive Biotechnologies Corporation (Nasdaq: ADPT), a commercial stage biotechnology company that aims to translate the genetics of the adaptive immune system into clinical products to diagnose and treat disease, today announced it will report financial results for the second quarter 2024 after market close on Thursday, August 1, 2024. Company management will webcast a corresponding conference call beginning at 1:30 p.m. Pacific Time / 4:30 p.m. Eastern Time. |
globenewswire.com |
2024-07-11 20:05:00 |
Czytaj oryginał (ang.) |
Adaptive Biotechnologies Announces Data Supporting the Clinical Benefits of MRD Assessment with clonoSEQ® To Be Presented at the Upcoming 2024 ASCO Annual Meeting and EHA2024 Hybrid Congress |
More than 20 abstracts will be presented from clinical trials and real-world evidence using clonoSEQ for MRD assessment across multiple types of blood cancers More than 20 abstracts will be presented from clinical trials and real-world evidence using clonoSEQ for MRD assessment across multiple types of blood cancers |
globenewswire.com |
2024-05-31 11:30:00 |
Czytaj oryginał (ang.) |